Cabometyx (cabozantinib tablets) — Cigna
Non-Small Cell Lung Cancer
Initial criteria
- Patient age ≥ 18 years
- Patient has a RET rearrangement positive tumor
- Patient has progressed on one of the first-line therapies, Gavreto (pralsetinib capsules) or Retevmo (selpercatinib capsules or tablets)
Approval duration
1 year